CA2911309A1 - Sobetirome in the treatment of myelination diseases - Google Patents

Sobetirome in the treatment of myelination diseases

Info

Publication number
CA2911309A1
CA2911309A1 CA2911309A CA2911309A CA2911309A1 CA 2911309 A1 CA2911309 A1 CA 2911309A1 CA 2911309 A CA2911309 A CA 2911309A CA 2911309 A CA2911309 A CA 2911309A CA 2911309 A1 CA2911309 A1 CA 2911309A1
Authority
CA
Canada
Prior art keywords
disease
sobetirome
pharmaceutically acceptable
acceptable salt
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2911309A
Other languages
English (en)
French (fr)
Inventor
Meredith HARTLEY
Andrew PLACZEK
Marco RIGHI
Dennis Bourdette
Gail Marracci
Priya CHAUDHARY
Thomas S. Scanlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
US Department of Veterans Affairs
Original Assignee
Oregon Health and Science University
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University, US Department of Veterans Affairs filed Critical Oregon Health and Science University
Publication of CA2911309A1 publication Critical patent/CA2911309A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2911309A 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases Abandoned CA2911309A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
US61/819,467 2013-05-03
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
USPCT/US2013/0053640 2013-08-05
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Publications (1)

Publication Number Publication Date
CA2911309A1 true CA2911309A1 (en) 2014-11-06

Family

ID=51843844

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2911309A Abandoned CA2911309A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Country Status (12)

Country Link
US (3) US10226438B2 (cg-RX-API-DMAC7.html)
EP (1) EP2991670B8 (cg-RX-API-DMAC7.html)
JP (4) JP2016517883A (cg-RX-API-DMAC7.html)
CN (1) CN105431163A (cg-RX-API-DMAC7.html)
AU (1) AU2014260468A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015027682A2 (cg-RX-API-DMAC7.html)
CA (1) CA2911309A1 (cg-RX-API-DMAC7.html)
ES (1) ES2745532T3 (cg-RX-API-DMAC7.html)
MX (2) MX379043B (cg-RX-API-DMAC7.html)
RU (1) RU2015151216A (cg-RX-API-DMAC7.html)
SG (2) SG10201709090UA (cg-RX-API-DMAC7.html)
WO (2) WO2014178892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
AU2015253100B2 (en) 2014-04-30 2018-01-18 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
CN115350285A (zh) 2014-08-13 2022-11-18 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
US20170119899A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
EP3445372A4 (en) * 2016-04-22 2020-03-25 Viking Therapeutics, Inc. USE OF THYROID BETA AGONISTS
EP3445373B1 (en) 2016-04-22 2024-08-21 Viking Therapeutics, Inc. Use of thyroid beta-agonists
LT3457851T (lt) 2016-05-18 2021-10-11 Oregon Health & Science University Sobetiromo dariniai
AU2017310535B2 (en) * 2016-08-12 2021-11-11 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
IL270169B2 (en) 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer preparations for use in angiography
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
US11660281B2 (en) 2017-06-29 2023-05-30 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
US11633433B2 (en) * 2017-07-18 2023-04-25 Keio University Anti-bacterial composition against TH1 cell-inducing bacteria
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
CN113423684A (zh) 2018-12-12 2021-09-21 速通医疗公司 新型拟甲状腺素药
US11667606B2 (en) 2019-03-01 2023-06-06 Autobahn Therapeutics, Inc. Thyromimetics
MX2022006470A (es) 2019-11-29 2022-08-04 Autobahn Therapeutics Inc Tiromimeticos novedosos.
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
WO1997021993A2 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
EP1003530A4 (en) 1996-08-20 2001-10-04 Univ California EYE TREATMENT USING SYNTHETIC THYROID HORMONE COMPOSITIONS
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
KR20010053277A (ko) 1998-06-30 2001-06-25 린다 에스. 스티븐슨 갑상선 호르몬 유사체 및 그 제조 방법
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CN1878545A (zh) * 2003-09-15 2006-12-13 奥德威研究院 甲状腺激素类似物及其使用方法
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
AU2005284879B2 (en) 2004-09-15 2011-04-14 Albany College Of Pharmacy And Health Sciences Thyroid hormone analogs for promoting angiogenesis
WO2006105205A1 (en) 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
KR20090071652A (ko) * 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
US8623861B2 (en) 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
PL2187882T3 (pl) * 2007-07-11 2013-05-31 Medicinova Inc Leczenie postępującej choroby neurodegeneracyjnej ibudilastem
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20160029870A (ko) * 2008-04-21 2016-03-15 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011343429B2 (en) 2010-12-16 2016-10-20 Sunovion Pharmaceuticals Inc. Sublingual films
JP6060268B2 (ja) * 2012-10-25 2017-01-11 ボルボ トラック コーポレイション 車両用電子制御エアブレーキシステム、そのようなシステムを備える車両及びそのようなシステムを制御する方法
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Also Published As

Publication number Publication date
WO2014178892A8 (en) 2015-12-17
EP2991670A1 (en) 2016-03-09
SG10201709090UA (en) 2017-12-28
MX379043B (es) 2025-03-10
JP6360552B2 (ja) 2018-07-18
WO2014178892A1 (en) 2014-11-06
WO2014178931A1 (en) 2014-11-06
US10226438B2 (en) 2019-03-12
JP6360552B6 (ja) 2018-08-15
US11510887B2 (en) 2022-11-29
WO2014178931A8 (en) 2015-11-26
EP2991670B1 (en) 2019-07-03
US20200405669A1 (en) 2020-12-31
JP2018162321A (ja) 2018-10-18
MX2015015228A (es) 2016-10-03
RU2015151216A (ru) 2017-06-08
AU2014260468A1 (en) 2015-11-19
US20190175531A1 (en) 2019-06-13
BR112015027682A2 (pt) 2017-08-29
US20160081955A1 (en) 2016-03-24
HK1222552A1 (en) 2017-07-07
EP2991670A4 (en) 2017-01-18
JP2016517883A (ja) 2016-06-20
JP2018141024A (ja) 2018-09-13
CN105431163A (zh) 2016-03-23
EP2991670B8 (en) 2019-09-11
JP2016517884A (ja) 2016-06-20
ES2745532T3 (es) 2020-03-02
SG11201509012QA (en) 2015-11-27
MX2021000538A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
US11510887B2 (en) Sobetirome in the treatment of myelination diseases
US20170326145A1 (en) Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
FR2807660A1 (fr) Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
CN110300581B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
JP2013527132A (ja) 中枢神経系（ｃｎｓ）の自己免疫性脱髄性疾患の治療において使用するためのジアゾキシド
US9956202B2 (en) Use of indolyl and indolinyl hydroxamates for treating neurodegenerative disorders or cognitive decicits
CN110248650A (zh) 用于增强突触发生和神经突发生的方法
JP6529634B1 (ja) アミロイドβ分解排出促進剤
US8557310B2 (en) Composition to retard the onset of symptoms of alzheimer's disease
US20230165810A1 (en) Fenfluramine for treatment of conditions associated with spreading depolarization
JP2011121976A (ja) 線維筋痛症に伴う口腔乾燥症を改善するための線維筋痛症に伴う口腔乾燥症改善用医薬組成物
WO2020250182A2 (ko) 지페노사이드 화합물을 유효성분으로 포함하는 퇴행성 신경질환 치료용 조성물
HK1222552B (en) Sobetirome in the treatment of myelination diseases
TWI726355B (zh) 苯甲酸或其鹽及衍生物用於預防或治療抗n-甲基-d-天冬胺酸受體腦炎之用途
KR102804780B1 (ko) 인지기능 장애의 치료용 조성물
RU2631887C2 (ru) Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения демиелинизирующих заболеваний живого организма, включая профилактику заболевания
KR20210113240A (ko) 신경 변성 질환의 예방 또는 치료약
WO2013049523A1 (en) Methods for reducing a-beta-1-42 levels, methods for reducing or preventing formation of amyloid plaques, and methods for improving cognitive function and memory retention in a subject
CA3102371C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis
US10624866B2 (en) Composition for prevention or treatment of chronic pain comprising Evans blue
RU2345763C1 (ru) Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин
KR20160018806A (ko) 연하장애 개선용 의약품

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200205